Valeant invests $10M in Laval plant upgrades
Enhances manufacturing capabilities and export capacity.
LAVAL, Que. — Valeant Canada is boosting its Canadian manufacturing and export capacity with a $10 million investment in its Laval, Que. headquarters.
The subsidiary of Valeant Pharmaceuticals International Inc., a multinational specialty pharmaceutical company, said the investment includes modernization of the plant with enhanced manufacturing technology “to ensure robust security of Valeant-manufactured products as they move through international distribution channels.”
The company said the investment ensures compliance with US regulatory requirements that will allow the plant to handle significant North American manufacturing mandates.
The plant currently exports 75% of its products across the continent.
Plant upgrades will get underway by the end of the year.
Valeant recently announced the transfer of the North American manufacturing mandate of antibiotic Arestin to Laval, an investment of $2.5 million that will create 15 new engineering and production jobs.